Turnstone Biologics Corp.

As of April 30, 2025, the market trend is mildly bearish, influenced by mixed indicators such as a mildly bullish weekly MACD and bearish RSI, with daily moving averages also showing a bearish stance.

Turnstone Biologics Corp. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $12 million and a market cap of $8.67 million. Key financial metrics include a negative P/E ratio, a 0.00% dividend yield, and a debt-to-equity ratio of -1.06.

As of Jun 18, Turnstone Biologics Corp. has a market capitalization of 8.67 million and reported net sales of 0.00 million with a net profit of -63.01 million over the last four quarters. Shareholder's funds are at 31.47 million, and total assets amount to 40.14 million.